scispace - formally typeset
Search or ask a question

What are the genetic driver/alteration in intrahepatic cholangiocarcinoma? 

Best insight from top research papers

Intrahepatic cholangiocarcinoma (ICC) is characterized by multiple genetic driver alterations. The most recurrent driver mutations in ICC include TP53, KRAS, SMAD4, IDH1/2, FGFR2-fus, and BAP1. These mutations exhibit pair-wise co-occurrences or mutual exclusivities and can be grouped into three genetic clusters. Cluster 1 is characterized by the tripartite interaction of KRAS, TP53, and SMAD4 mutations and is associated with a large bile duct histological phenotype and poor prognosis. Cluster 2 is characterized by co-association of IDH/BAP1 or FGFR2-fus/BAP1 mutations and is associated with a small bile duct phenotype and better prognosis. Cluster 3 consists of mutation-free ICC cases with intermediate clinicopathological features. Additionally, S100P and KRT17 have been identified as biomarkers that can stratify Cluster 3 ICCs into two distinct subtypes based on their biological and clinical characteristics.

Answers from top 4 papers

More filters
Papers (4)Insight
The paper identifies seven recurrent driver mutations in intrahepatic cholangiocarcinoma: TP53, KRAS, SMAD4, IDH1/2, FGFR2-fus, and BAP1.
The paper identifies 12 significantly mutated genes and 5 focal copy number alteration regions in intrahepatic cholangiocarcinoma (iCCA).
The genetic driver alterations in intrahepatic cholangiocarcinoma include IDH1 R132C, KRAS, SMAD4, ERBB2 gain, MDM2 gain, CKDN2A loss, and TERT alterations.
The genetic driver alterations in intrahepatic cholangiocarcinoma (iCCA) include FGFR2 gene fusions, NTRK1 fusions, FGFR1 fusions, FGFR3 fusions, FGFR4 fusions, ROS1 mutations, MET mutations, ALK mutations, IDH1 mutations, BRAF mutations, FGFR2 mutations, FGFR3 mutations, IDH2 mutations, and EGFR mutations.

Related Questions

What are the molecular genetics of colorectal cancer?5 answersColorectal cancer (CRC) has been extensively studied at the molecular level. Genetic alterations play a crucial role in the development and progression of CRC. Several hereditary CRC syndromes have been identified, including familial adenomatous polyposis (FAP) and Lynch syndrome (LS). Pathogenic variants in cancer-predisposing genes have been found in up to 10% of CRC cases. Molecular phenotypes of tumors can help identify individuals with genetic susceptibility to CRC and guide precision prevention and treatment strategies. Molecular diagnostics are essential for planning the management of CRC patients, including the choice of systemic treatment. Molecular testing of the tumor is necessary to assess the presence of specific genetic alterations, such as KRAS and NRAS mutations, which impact treatment decisions. Additionally, the molecular characteristics of CRC, including DNA, RNA, and protein-level alterations, are being studied to better understand the biology of the disease and develop targeted therapies.
What are the commonly mutated germline breast cancer genes?4 answersGermline mutations in breast cancer susceptibility genes BRCA1 and BRCA2 (gBRCA1/2) are commonly observed in breast cancer patients. The frequency of these mutations varies among different populations. In Asian populations, gBRCA1/2 mutations are associated with an elevated risk of breast cancer in young women. In Korean breast cancer patients, the most frequently mutated genes in gBRCA1/2 are Val1833Ser, Glu1210Arg, Tyr130Ter in BRCA1, and Arg2494Ter, Lys467Ter in BRCA2. In Hispanic populations in the United States and Central American countries, the most frequently mutated genes in gBRCA1/2 are BRCA1, BRCA2, PALB2, CHEK2, ATM, and TP53. In Egyptian patients, the major genes harboring pathogenic mutations in gBRCA1/2 are ATM, BRCA2, BRCA1, VHL, MSH6, APC, CHEK2, MSH2, MEN1, PALB2, and MUTYH. These findings highlight the genetic heterogeneity of breast cancer patients with gBRCA1/2 mutations across different populations.
Which novel genes are responsible for hepatocellular carcinoma?4 answersNovel genes responsible for hepatocellular carcinoma (HCC) include ADCK3, HK3, PPT1, CDKN2A, DLAT, DLST, GLS, PDHA1, MT1M, SPINK1, AKR1B10, SLCO1B3, ADH4, COL15A1, RET, and KCNJ16. These genes have been identified through bioinformatics analysis, differential expression analysis, and functional enrichment pathways. They are involved in various biological processes such as immune/inflammatory responses, fatty acid elongation, mitochondrion function, and metabolic pathways. Some of these genes, such as CDKN2A, have been found to be independent factors for HCC prognosis and may be associated with immune-cell infiltration, tumor mutation burden, microsatellite instability, and immune checkpoints. The diagnostic model based on these genes, such as MT1M, SPINK1, AKR1B10, and SLCO1B3, can effectively stratify HCC patients and provide predictive significance for diagnosis. These findings provide potential prognostic predictors and therapeutic targets for HCC patients.
XRCCI (c.1517G>C) polymorphism could be associated with increased risk of HCV-related HCC?5 answersThe XRCC1 Arg280His polymorphism is associated with a significantly increased risk of HCC. However, there is no specific mention of XRCCI (c.1517G>C) polymorphism in any of the provided abstracts. Therefore, we cannot determine if XRCCI (c.1517G>C) polymorphism is associated with an increased risk of HCV-related HCC based on the information provided.
Which genes affect changes in breast cancer?5 answersDifferentially expressed genes that affect changes in breast cancer include CD36, LEP, LPL, ADIPOQ, PCK1, ACASL1, PPARG, PLIN1, ACACB, and PPARG. Recurrent ESR1 gene fusions, particularly with diverse partner genes, are indicative of ligand-independent hyperactivity in hormone-sensitive metastatic breast cancers. Driver mutations in breast cancer have been identified in several genes, including AKT2, ARID1B, CASP8, CDKN1B, MAP3K1, MAP3K13, NCOR1, SMARCD1, and TBX3. Tumor suppressor genes BRCA1 and BRCA2 are known to be involved in the development of familial breast cancers. Gene alterations in breast cancer can involve tumor suppressor genes, repair-mutator genes, and oncogenes, with common genetic abnormalities found in specific chromosome regions.
How does bile acids effect cholangiocarcinoma cells?5 answersBile acids have been implicated in the development and progression of cholangiocarcinoma (CCA). Bile acids are amphipathic compounds that act as signaling molecules and inflammatory agents, and they can activate transcriptional factors and cellular signaling pathways involved in metabolism. Omega-3 polyunsaturated fatty acids (n-3 PUFAs), found in fish oil, have been shown to inhibit the proliferation of CCA cells and suppress migration and invasion potential. The bile acid receptors FXR and TGR5 play a role in CCA progression, with FXR inhibiting and TGR5 promoting CCA growth and metastasis. Conjugated bile acids, specifically, have been found to stimulate CCA cell growth and invasiveness through the activation of the sphingosine 1-phosphate receptor 2 (S1PR2). Modulating the activity of bile acids and their receptors may hold potential as therapeutic strategies for CCA.

See what other people are reading

What are the current research directions for Parkinson's disease?
4 answers
Current research directions for Parkinson's disease (PD) include studying the relationship between PD and depression, exploring new approach methodologies (NAMs) for drug discovery, investigating the association between PD and metabolic syndrome (MetS), highlighting the importance of non-motor symptoms in PD research, and recognizing PD as a collection of multiple diseases. Studies have focused on the pathogenesis of PD depression, including the influence of genes, nutritional factors, and proteins, as well as the development of new treatment methods such as drug therapy, behavioral therapy, and psychotherapy. NAMs are being explored to advance PD research and move away from animal-based research, with recommendations including integrating NAMs, learning from Alzheimer's disease research, and increasing data sharing. The association between MetS and PD is being investigated, with potential therapeutic strategies being explored. Non-motor symptoms, such as sleep disorders and gut symptoms, are being emphasized in PD research. PD is being recognized as a collection of multiple diseases, leading to the need for informative patient stratification and personalized approaches to diagnosis and treatment.
Imaging modality cholelithiasis?
4 answers
Ultrasound (US) is the recommended initial imaging modality for cholelithiasis due to its wide availability, speed, and superior spatial resolution. It is excellent in detecting cholelithiasis and acute cholecystitis. Computed tomography (CT) is also used for imaging cholelithiasis and is particularly useful in detecting complications such as infected postoperative fluid collections, biliary obstruction, and biliary infection. Magnetic resonance imaging (MRI) has advantages over CT as it does not use ionizing radiation and can be done without contrast. It is not affected by the internal composition of the stone and can be used to determine the cause and location of biliary obstruction. Magnetic resonance cholangiopancreatography (MRCP) can also be used to evaluate the biliary tract, but it is limited in detecting small stones and evaluating the biliary tract near the ampulla.
What are the mechanisms of cancer resistance to CDK4/6 inhibitors?
4 answers
Resistance to CDK4/6 inhibitors in cancer can occur through various mechanisms. These include genetic alterations such as RB1 loss, activating alterations in AKT1, RAS, AURKA, CCNE2, ERBB2, and FGFR2, and loss of estrogen receptor expression. Metabolic and transport variations among different CDK4/6 inhibitors, such as Abemaciclib, Palbociclib, and Ribociclib, can also contribute to resistance. Additionally, resistance can arise from gene alteration, pathway dysregulation, and changes in the tumor microenvironment. Biomarkers have shown potential in predicting drug resistance and have prognostic value. Preclinical studies have demonstrated that modified treatment strategies based on CDK4/6 inhibitors can be effective against drug-resistant tumors. Understanding these mechanisms of resistance is crucial for the development of novel therapeutic strategies to overcome resistance and improve patient outcomes.
The MAPK pathway in human?
5 answers
The MAPK pathway is a crucial regulator of cellular processes involved in cancer development and progression. Mutations in MAPK pathway genes have been identified in various human cancers, and these mutations are associated with poor disease outcomes. In head and neck squamous cell carcinoma (HNSCC), nearly 1/5 of cases have MAPK pathway mutations, which are largely activating mutations. Recent clinical evidence has shown promising results in targeting specific mutations in the MAPK pathway for precision therapy in HNSCC patients. Additionally, the MAPK pathway has been implicated in apoptosis in human lung epithelial cells, specifically through the JNK and P38 pathways. These findings highlight the importance of understanding the MAPK pathway in human diseases and suggest potential therapeutic strategies for targeting this pathway.
Is "ICOSLG" a biomarker of immunotherapy?
5 answers
ICOSLG is a potential biomarker of immunotherapy. High expression of ICOSLG has been observed in colorectal cancer (CRC) and is positively correlated with CD4+/Foxp3+ tumor-infiltrating lymphocyte density and PD-1/PD-L1 expression. Increased ICOSLG expression may be associated with the progressive formation of Foxp3+ TILs in the immune microenvironment and further promote the development of abnormal cytology in colorectal lesions. In glioblastoma (GBM), upregulation of ICOSLG expression is associated with poor prognosis and is preferentially expressed in mesenchymal GBM sphere cells (GSCs). ICOSLG expression by mesenchymal GSCs promotes expansion of T cells that produce interleukin-10, suggesting a role in immunosuppression. Inhibition of the ICOSLG-inducible co-stimulator axis may provide a promising immunotherapeutic approach for suppressing a subset of GBM with an elevated mesenchymal signature. Overall, ICOSLG expression appears to be associated with immune modulation and may serve as a biomarker for immunotherapy in CRC and GBM.
What is Colorectal cancer?
5 answers
Colorectal cancer (CRC) is a common cancer that affects both men and women globally. It is the third most diagnosed cancer worldwide and the second leading cause of death in patients with cancer. CRC can be attributed to various risk factors such as an unhealthy diet, tobacco use, high body mass index, and low physical activity. Screening for CRC is important for early detection, and methods such as faecal blood tests and colonoscopy are used for systematic screening. Treatment for CRC involves surgery, radiotherapy, and/or systemic chemotherapy, which may be tailored based on selected immune-markers. Multidisciplinary care and the inclusion of treatment in universal health care packages are essential for providing high-quality care to CRC patients. Collaborative efforts are needed to combat the increasing burden of CRC due to current trends and an aging population.
What is the incidence of cancer in Indonesia?
5 answers
The incidence of cancer in Indonesia is quite high, with breast cancer being the most common type. According to the Basic Health Research (Riskesdas) data in 2013, the prevalence of tumors/cancer in Indonesia is 1.4 per 1000 population. Data from the Global Cancer Observatory (GLOBOCAN) 2020 shows that breast cancer accounts for 16.6% of the total new cancer cases in Indonesia, with a mortality rate of more than 22 million. Lung cancer is also a significant contributor to cancer incidence and mortality in Indonesia, accounting for 8.6% of all cancer cases in 2018. The total number of cancer cases in Indonesia is estimated to be 396,914 in 2020. However, it is important to note that the incidence of cancer may vary depending on the specific type and age group being studied.
Overview of colorectal liver metastesis cancer?
4 answers
Colorectal cancer (CRC) is a common cancer and a leading cause of cancer-related deaths worldwide. Approximately 35% of CRC patients have liver metastases at the time of diagnosis, which significantly impacts prognosis. Surgical resection of liver metastases is the only treatment that offers a chance of increasing the 5-year survival rate up to 45-60%. However, many patients will recur after resection or present with unresectable disease, leading to a 5-year survival rate of only about 20% for unresectable metastatic CRC. Molecular cancer biomarkers play a crucial role in personalizing treatment and predicting outcomes for CRC patients with liver metastases. Several biomarkers, such as KRAS, NRAS, BRAF V600E mutations, DNA mismatch repair deficiency/microsatellite instability status, HER2 amplification, and NTRK fusions, have been identified as actionable molecular biomarkers for CRC. A multidisciplinary team approach is essential for determining the treatment strategy, including surgery, systemic therapy, and liver-directed therapies, to improve outcomes for patients with CRC liver metastasis. Further research is needed to understand the relationship between alcohol consumption, liver injury, and the risk of colorectal liver metastasis, as well as to identify new therapeutic options.
What is the relationship between PD-L1 expression and TILs?
5 answers
PD-L1 expression is positively associated with tumor-infiltrating lymphocytes (TILs) in breast cancer. In invasive carcinoma of the breast, both PD-L1 and TILs showed maximum positivity in grade 3 carcinoma. PD-L1 expression in TILs was correlated with different degrees of lymphocytic infiltration in melanoma tumor microenvironment cells.
What are the biomarkers realted with early stages of the melanoma?
4 answers
Biomarkers related to early stages of melanoma include melanoma-associated antigens (MAAs), S100B, microRNAs (miRNAs), circulating tumor cells (CTCs), lactate dehydrogenase (LDH), and extracellular vesicles. These biomarkers have the potential to aid in the detection, diagnosis, prognosis, and monitoring of melanoma. Specifically, miRNAs such as hsa-miR-149-3p, hsa-miR-150-5p, hsa-miR-21-5p, hsa-miR-200c-3p, hsa-miR-134-5p, hsa-miR-144-3p, and hsa-miR-221-3p have been found to be differentially expressed in plasma-derived exosomes from melanoma patients and controls, making them promising ancillary tools for melanoma diagnosis and discrimination between nevi and melanoma. Additionally, a proprietary 7-protein immunohistochemistry (7-P-IHC) signature has shown high sensitivity and risk enhancement ability in identifying patients at high risk of relapse in stage IB/IIA melanoma, making it a potential biomarker for adjuvant therapy selection. These biomarkers provide valuable insights into the early stages of melanoma and have the potential to improve early detection and personalized treatment approaches.
What is the difference in prognosis among breast cancer subtypes?
5 answers
Breast cancer subtypes have different prognoses. Luminal A subtype has the best prognosis, while triple-negative subtype has the worst prognosis. Luminal B subtype has a moderate prognosis, with Luminal B (HER2-) and Luminal B (HER2+) subtypes falling in this category. Invasive lobular carcinoma (ILC) has a poorer prognosis compared to invasive ductal carcinoma (IDC) in all subtypes. Late recurrence is a poor prognostic factor for overall survival (OS) in the luminal B subtype. The luminal B subtype also has a high rate of late recurrence. The presence of hormone receptors and HER2 status also influence prognosis, with hormone receptor-positive tumors being more frequent in the late recurrence group. Different therapeutic approaches are needed for a better prognosis in luminal ILC compared to luminal IDC.